What is the share price of Bliss GVS Pharma Ltd (BLISSGVS) today?
The share price of BLISSGVS as on 30th April 2025 is ₹119.71. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Bliss GVS Pharma Ltd (BLISSGVS) share?
The past returns of Bliss GVS Pharma Ltd (BLISSGVS) share are- Past 1 week: -3.16%
- Past 1 month: 6.59%
- Past 3 months: -16.07%
- Past 6 months: -0.73%
- Past 1 year: -1.17%
- Past 3 years: 52.81%
- Past 5 years: 23.52%
What are the peers or stocks similar to Bliss GVS Pharma Ltd (BLISSGVS)?
The peers or stocks similar to Bliss GVS Pharma Ltd (BLISSGVS) include:What is the dividend yield % of Bliss GVS Pharma Ltd (BLISSGVS) share?
The current dividend yield of Bliss GVS Pharma Ltd (BLISSGVS) is 0.40.What is the market cap of Bliss GVS Pharma Ltd (BLISSGVS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bliss GVS Pharma Ltd (BLISSGVS) is ₹1297.00 Cr as of 30th April 2025.What is the 52 week high and low of Bliss GVS Pharma Ltd (BLISSGVS) share?
The 52-week high of Bliss GVS Pharma Ltd (BLISSGVS) is ₹185.50 and the 52-week low is ₹92.15.What is the PE and PB ratio of Bliss GVS Pharma Ltd (BLISSGVS) stock?
The P/E (price-to-earnings) ratio of Bliss GVS Pharma Ltd (BLISSGVS) is 17.19. The P/B (price-to-book) ratio is 1.29.Which sector does Bliss GVS Pharma Ltd (BLISSGVS) belong to?
Bliss GVS Pharma Ltd (BLISSGVS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Bliss GVS Pharma Ltd (BLISSGVS) shares?
You can directly buy Bliss GVS Pharma Ltd (BLISSGVS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Bliss GVS Pharma Ltd
BLISSGVS Share Price
119.712.75% (-3.38)
BLISSGVS Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
BLISSGVS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 21.75 | 1.29 | 0.40% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.81 | 6.38 | 0.53% |
BLISSGVS Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
BLISSGVS Company Profile
Bliss GVS Pharma Limited is engaged in developing, manufacturing and marketing pharmaceutical formulations.
BLISSGVS Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
45.24
1Y Return
18.66%
Buy Reco %
88.24
CIPLA
PE Ratio
30.21
1Y Return
9.48%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
67.89
1Y Return
23.64%
Buy Reco %
68.00
MANKIND
PE Ratio
55.15
1Y Return
7.57%
Buy Reco %
81.25
DRREDDY
PE Ratio
17.54
1Y Return
6.62%
Buy Reco %
46.67
BLISSGVS Forecasts
Price
Revenue
Earnings
BLISSGVS Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeBLISSGVS Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeBLISSGVS Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeBLISSGVS
Income
Balance Sheet
Cash Flow
Annual Normal View
BLISSGVS Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 571.24 | 810.94 | 841.18 | 936.20 | 728.50 | 597.43 | 778.94 | 769.38 | 798.98 | 839.90 | ||||||||||
Raw Materials | 262.55 | 368.69 | 391.70 | 618.79 | 435.67 | 341.59 | 420.18 | 374.38 | 390.46 | 705.12 | ||||||||||
| Power & Fuel Cost | 4.72 | 5.58 | 5.49 | 4.76 | 5.88 | 8.14 | 8.25 | 7.13 | 10.43 | |||||||||||
| Employee Cost | 33.74 | 61.35 | 69.23 | 42.32 | 53.69 | 68.09 | 76.15 | 86.17 | 95.58 | |||||||||||
| Selling & Administrative Expenses | 67.19 | 117.90 | 87.57 | 49.96 | 45.30 | 44.91 | 80.65 | 80.45 | 85.89 | |||||||||||
| Operating & Other expenses | 22.98 | 42.19 | 97.72 | 25.10 | 38.83 | 7.82 | 117.48 | 86.13 | 66.45 | |||||||||||
EBITDA | 180.06 | 215.23 | 189.47 | 195.27 | 149.13 | 126.88 | 76.23 | 135.12 | 150.17 | 134.78 | ||||||||||
| Depreciation/Amortization | 13.26 | 20.14 | 21.38 | 8.94 | 12.59 | 17.23 | 17.33 | 18.67 | 26.38 | 28.23 | ||||||||||
| PBIT | 166.80 | 195.09 | 168.09 | 186.33 | 136.54 | 109.65 | 58.90 | 116.45 | 123.79 | 106.55 | ||||||||||
| Interest & Other Items | 18.61 | 19.69 | 22.80 | 4.41 | 7.57 | 5.51 | 4.74 | 10.36 | 6.91 | 8.29 | ||||||||||
| PBT | 148.19 | 175.40 | 145.29 | 181.92 | 128.97 | 104.14 | 54.16 | 106.09 | 116.88 | 98.26 | ||||||||||
| Taxes & Other Items | 65.71 | 93.36 | 86.51 | 58.19 | 31.71 | 35.63 | 39.13 | 35.22 | 41.41 | 38.62 | ||||||||||
| Net Income | 82.48 | 82.04 | 58.78 | 123.73 | 97.26 | 68.51 | 15.03 | 70.87 | 75.47 | 59.64 | ||||||||||
| EPS | 8.00 | 7.95 | 5.70 | 12.00 | 9.43 | 6.64 | 1.45 | 6.82 | 7.23 | 5.70 | ||||||||||
| DPS | 0.50 | 0.60 | 1.00 | 1.00 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | ||||||||||
| Payout ratio | 0.06 | 0.08 | 0.18 | 0.08 | 0.05 | 0.08 | 0.34 | 0.07 | 0.07 | 0.09 |
BLISSGVS Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFBLISSGVS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Bliss GVS Pharma Ltd | 17.19 | 1.29 | 0.40% |
| Sun Pharmaceutical Industries Ltd | 45.24 | 6.46 | 0.75% |
| Cipla Ltd | 30.21 | 4.65 | 0.84% |
| Torrent Pharmaceuticals Ltd | 67.89 | 16.40 | 0.84% |
BLISSGVS Stock Price Comparison
Compare BLISSGVS with any stock or ETFCompare BLISSGVS with any stock or ETF
BLISSGVS
BLISSGVS Shareholdings
BLISSGVS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
BLISSGVS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
BLISSGVS Shareholding Pattern
BLISSGVS Shareholding History
Foreign Institutions
Mutual Funds Invested in BLISSGVS
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 1 Mutual Funds holding Bliss GVS Pharma Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0008% | Percentage of the fund’s portfolio invested in the stock 0.06% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 87/110 (-9) |
Compare 3-month MF holding change on Screener
smallcases containing BLISSGVS stock
Looks like this stock is not in any smallcase yet.
BLISSGVS Events
BLISSGVS Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BLISSGVS has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.40%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹4.04 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
BLISSGVS Upcoming Dividends
No upcoming dividends are available
BLISSGVS Past Dividends
Cash Dividend
Ex DateEx DateJul 18, 2024
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Jul 18, 2024
Cash Dividend
Ex DateEx DateJul 12, 2023
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Jul 12, 2023
Cash Dividend
Ex DateEx DateJun 20, 2022
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Jun 20, 2022
Cash Dividend
Ex DateEx DateSep 13, 2021
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 13, 2021
Cash Dividend
Ex DateEx DateSep 17, 2020
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 17, 2020
BLISSGVS Stock News & Opinions
Articles & Videos
Earnings
Bliss GVS Pharma consolidated net profit declines 13.80% in the December 2024 quarter
Net profit of Bliss GVS Pharma declined 13.80% to Rs 23.80 crore in the quarter ended December 2024 as against Rs 27.61 crore during the previous quarter ended December 2023. Sales rose 4.83% to Rs 210.42 crore in the quarter ended December 2024 as against Rs 200.72 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales210.42200.72 5 OPM %14.1521.77 - PBDT43.9747.00 -6 PBT36.4240.04 -9 NP23.8027.61 -14 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Bliss GVS Pharma schedules board meeting
Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 28 January 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Bliss GVS Pharma allots 34,250 equity shares under ESOP
Bliss GVS Pharma has allotted 34,250 equity shares under ESOP on 06 December 2024. With this allotment, the paid up equity share capital has increased to 10,53,66,272 equity shares of Re. 1/- each aggregating Rs. 10,53,66,272/-. Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Bliss GVS Pharma soars after manufacturing units get GMP certificate from Romania medical authority
In a regulatory filing made on Saturday, the company informed that its manufacturing facilities located at Aliyali Village and Vevoor Village in Palghar district of Maharashtra has received a Certificate of GMP (good manufacturing practice) Compliance from the National Agency for Medicines and Medical Devices of Romania (NAMMDR). The compliance certificate has been granted following an EU GMP inspection that took place on 30th November and 1st December 2023 at the said facilities. Bliss develops and manufactures pharmaceutical formulations mainly for sale in Africa. The company sells formulations in the form of suppositories, pessaries, capsules, tablets, and syrups. It manufactures more than 250 branded formulations in the anti-malarial, anti-fungal, anti-bacterial, anti-biotic, anti-inflammatory, contraceptive, and anti-diabetic segments. Bliss also contract-manufactures suppositories and pessaries for Sun Pharma and Mankind. The company's consolidated net profit declined 42.66% to Rs 24.26 crore despite a 2.74% rise in net sales to Rs 217.68 crore in Q2 FY25 as compared with Q2 FY24. Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Bliss GVS Pharma's manufacturing facilities complete EU GMP inspection
Bliss GVS Pharma announced that the company's manufacturing facility situated at Plot No. 11, Dewan Udyog Nagar, Aliyali Village, Palghar, 401404, India and Survey No. 43-44, Vevoor Village, 401404, India, has successfully received a Certificate of GMP (Good Manufacturing Practice) Compliance from the National Agency for Medicines and Medical Devices of Romania (NAMMDR) following an EU GMP inspection that took place on 30 November and 1 December 2023. Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Bliss GVS Pharma consolidated net profit declines 42.66% in the September 2024 quarter
Net profit of Bliss GVS Pharma declined 42.66% to Rs 24.26 crore in the quarter ended September 2024 as against Rs 42.31 crore during the previous quarter ended September 2023. Sales rose 2.74% to Rs 217.68 crore in the quarter ended September 2024 as against Rs 211.88 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales217.68211.88 3 OPM %19.0525.66 - PBDT42.6965.52 -35 PBT35.7159.13 -40 NP24.2642.31 -43 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Bliss GVS Pharma to table results
Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Bliss GVS Pharma allots 1.57 lakh equity shares under ESOP
Bliss GVS Pharma has allotted 157,550 equity shares under ESOP on 04 October 2024. With this allotment, the paid up equity share capital has increased to 10,53,02,022 equity shares of Re. 1/- each aggregating Rs. 10,53,02,022/-. Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Bliss GVS Pharma to convene board meeting
Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 24 July 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Bliss GVS Pharma declines after Palghar units gets Form 483 with 3 observations from US FDA
2 years agoBusiness Standard
Over the last 5 years, revenue has grown at a yearly rate of -3.12%, vs industry avg of 9.04%
Over the last 5 years, market share decreased from 0.43% to 0.21%
Over the last 5 years, net income has grown at a yearly rate of -9.41%, vs industry avg of 15.28%